Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)–streptavidin (SA) conjugate and DOTA-biotin labeled with β-emitting radionuclides has been explored as a strategy to decrease relapse and toxicity. α-emitting radionuclides exhibit high cytotoxicity coupled with a short path leng...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pagel, John M., Kenoyer, Aimee L., Bäck, Tom, Hamlin, Donald K., Wilbur, D. Scott, Fisher, Darrell R., Park, Steven I., Frayo, Shani, Axtman, Amanda, Orgun, Nural, Orozco, Johnnie, Shenoi, Jaideep, Lin, Yukang, Gopal, Ajay K., Green, Damian J., Appelbaum, Frederick R., Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3142907/
https://ncbi.nlm.nih.gov/pubmed/21613259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-347039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados